Posters/Publications

paper

First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors

EClinicalMedicine

Date - 04/2021

oral

Novel, first-in-class, fatty acid synthase inhibitor, TVB-2640 versus placebo demonstrates clinically significant reduction in liver fat by MRI-PDFF in NASH

AASLD

Date - 11/2020

oral

TVB-2640 with Bevacizumab in Relapsed High-grade Astrocytoma

European Society for Medical Oncology (ESMO) Congress

Date - 09/2020

oral

Novel, first-in-class, fatty acid synthase inhibitor, TVB-2640 versus placebo demonstrates clinically significant reduction in liver fat by MRI-PDFF in NASH

EASL International Liver Congress

Date - 08/2020

poster

The FASN inhibitor TVB-2640 is efficacious in a new 3D human liver microtissue model of NASH

EASL International Liver Congress

Date - 08/2020

paper

Fatty Acid Synthase Inhibitor TVB-2640 Reduces Hepatic de Novo Lipogenesis in Males With Metabolic Abnormalities

Hepatology 2020

Date - 07/2020

oral

FASN inhibitor TVB-2640 in NASH

NASH-TAG

Date - 01/2020

poster

Updated Results from a Prospective Phase 2 Study in Patients with First Relapse of High-grade Astrocytoma Using TVB-2640 in Combination with bevacizumab

ASCO

Date - 06/2019

poster

FASN inhibition as a potential treatment for therapy of endocrine resistant breast cancer

San Antonio Breast Cancer Symposium

Date - 12/2018

poster

Fibroblast Growth Factor-21 and its Relationship to Human Liver Fat Synthesis; Impact of a New Therapeutic Agent

ObesityWeek

Date - 11/2018

Posters/Publications

First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors

Novel, first-in-class, fatty acid synthase inhibitor, TVB-2640 versus placebo demonstrates clinically significant reduction in liver fat by MRI-PDFF in NASH

TVB-2640 with Bevacizumab in Relapsed High-grade Astrocytoma

Novel, first-in-class, fatty acid synthase inhibitor, TVB-2640 versus placebo demonstrates clinically significant reduction in liver fat by MRI-PDFF in NASH

The FASN inhibitor TVB-2640 is efficacious in a new 3D human liver microtissue model of NASH

Fatty Acid Synthase Inhibitor TVB-2640 Reduces Hepatic de Novo Lipogenesis in Males With Metabolic Abnormalities

FASN inhibitor TVB-2640 in NASH

Updated Results from a Prospective Phase 2 Study in Patients with First Relapse of High-grade Astrocytoma Using TVB-2640 in Combination with bevacizumab

FASN inhibition as a potential treatment for therapy of endocrine resistant breast cancer

Fibroblast Growth Factor-21 and its Relationship to Human Liver Fat Synthesis; Impact of a New Therapeutic Agent

Site map

Contact us